Evidence map›Paper›PMID 40949755›Full record

ArticleArXiv2025

Network-driven discovery of repurposable drugs targeting hallmarks of aging.

Bnaya Gross, Joseph Ehlert, Vadim N Gladyshev, Joseph Loscalzo, Albert-László Barabási

Abstract readPreprint
In one paragraph

Article in ArXiv, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

5 authors.

Bnaya GrossNetwork Science Institute, Northeastern University, Boston, MA 02115.
Joseph EhlertNetwork Science Institute, Northeastern University, Boston, MA 02115.
Vadim N GladyshevDepartment of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115.
Joseph LoscalzoDepartment of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115.
Albert-László BarabásiNetwork Science Institute, Northeastern University, Boston, MA 02115.

Funding

L-2-Hydroxyglutarate and Metabolic Remodeling in HypoxiaR01HL155107 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI Joseph Loscalzo · 2021 to 2026
$4.1M
Branched-chain Keto-acids and Aerobic Glycolysis in Vascular Smooth Muscle CellsR01HL166137 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI Joseph Loscalzo · 2023 to 2026
$2.8M
NHLBI NIH HHS R01 HL155107NHLBI NIH HHS R01 HL166137
6 · The paper itself

Abstract

Despite the thousands of genes implicated in age-related phenotypes, effective interventions for aging remain elusive, a lack of advance rooted in the multifactorial nature of longevity and the functional interconnectedness of the molecular components implicated in aging. Here, we introduce a network medicine framework that integrates 2,358 longevity-associated genes onto the human interactome to identify existing drugs that can modulate aging processes. We find that genes associated with each hallmark of aging form a connected subgraph, or hallmark module, a discovery enabling us to measure the proximity of 6,442 clinically approved or experimental compounds to each hallmark. We then introduce a transcription-based metric,

Identifiers

PMID40949755
PMCPMC12425021

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.